Repertoire Immune Medicines
PrivateLast Round
Series B
Apr 13, 2021
Total Funding Raised
$409M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Repertoire Immune Medicines operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B round in April 2021.
Repertoire Immune Medicines is a biotechnology company that develops targeted therapies for cancer, autoimmune disorders, and infectious diseases using its proprietary DECODE platform to map T cell receptor-antigen interactions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Repertoire Immune Medicines Comparables
Compare Repertoire Immune Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 3T Biosciences | 84% | |
| BlueSphere Bio | 81% | |
| Enara Bio | 79% |
For institutional investors. Book with your work email.
Repertoire Immune Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 13, 2021 | ||||
| Grant | Jun 24, 2020 | ||||
| Early Funding | Mar 12, 2020 | ||||
| Series A | Nov 14, 2017 |
For institutional investors. Book with your work email.
Repertoire Immune Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series B |
| Public Sector Pension Investment Board | Series B |
| Covid19 HPC Consortium | Grant |
| SoftBank Group | Series B |
| Invus Opportunities | Series B |
| JDRF | Early Funding |
| Flagship Pioneering | Series B, Series A, Early Funding, Founding |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 31% MoM, reaching 6.1K.
- Apr 1, 2026
Announced strategic collaboration with Pfizer.
For institutional investors. Book with your work email.
Repertoire Immune Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Repertoire Immune Medicines's valuation, stock price, and market status.
Is Repertoire Immune Medicines a public or private company?
Repertoire Immune Medicines is a private company.
What is the current stock price of Repertoire Immune Medicines?
Repertoire Immune Medicines is a private company, so its shares have no public market price. Caplight tracks Repertoire Immune Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Repertoire Immune Medicines worth (valuation)?
Valuation information for Repertoire Immune Medicines is not publicly available.
Can I buy Repertoire Immune Medicines stock?
Repertoire Immune Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Repertoire Immune Medicines's last funding round?
Repertoire Immune Medicines's most recent funding round was Series B on April 13, 2021.
Who are the main investors in Repertoire Immune Medicines?
Key investors in Repertoire Immune Medicines include Flagship Pioneering.
Will Repertoire Immune Medicines IPO soon?
No public IPO plans have been announced for Repertoire Immune Medicines.
How can I track Repertoire Immune Medicines secondary market activity?
Caplight tracks bids, offers, and trades in Repertoire Immune Medicines's shares on secondary markets.